NRX-4972

NRX-4972 is an orally bioavailable, highly selective degrader of Aurora A kinase (AURKA), developed by Nurix Therapeutics. It is a proteolysis-targeting chimera (PROTAC) small molecule designed to induce targeted degradation of the AURKA protein, which plays a critical role in cell cycle regulation and is frequently overexpressed in various cancers. Unlike traditional inhibitors, NRX-4972 leverages protein degradation to maximize target coverage and efficacy, including against kinase-independent functions of AURKA that are not addressed by enzymatic inhibition. Preclinical studies have demonstrated that NRX-4972 penetrates the central nervous system (CNS), downregulates MYCN expression, induces DNA damage, apoptosis, and G2/M cell cycle arrest more effectively than standard AURKA inhibitors. The compound has shown significant anti-tumor activity in neuroblastoma and small cell lung cancer models and is being explored for its potential across pediatric and adult cancers[1][3][4][5][7].